A Phase I Clinical Trial to Evaluate the Safety and Tolerability of a Single Dose of Human Umbilical Cord Mesenchymal Stem Cell Injection (IxCell hUC-MSC-P) in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
Latest Information Update: 20 Feb 2025
At a glance
- Drugs Umbilical cord mesenchymal stem cell therapy Shanghai IxCell Biotechnology (Primary)
- Indications Interstitial lung diseases
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shanghai IxCell Biotechnology
Most Recent Events
- 20 Feb 2025 New trial record